Ocular and Plasma Pharmacokinetics of Enavogliflozin Ophthalmic Solution in Preclinical Speciesopen access
- Authors
- Jang, Mingui; Kang, Minsung; Lee, Eunseok; Shin, Dongseong
- Issue Date
- Jan-2024
- Publisher
- MDPI
- Keywords
- enavogliflozin; SGLT2 inhibitor; ocular pharmacokinetics; diabetic retinopathy; diabetic macular edema
- Citation
- PHARMACEUTICALS, v.17, no.1
- Journal Title
- PHARMACEUTICALS
- Volume
- 17
- Number
- 1
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90436
- DOI
- 10.3390/ph17010111
- ISSN
- 1424-8247
1424-8247
- Abstract
- An enavogliflozin ophthalmic solution (DWRX2008) is being developed to treat diabetic retinopathy and macular edema. This study evaluated the ocular distribution and plasma pharmacokinetics (PKs) of enavogliflozin in animal species. A sample of [14C] enavogliflozin was ocularly administered to two rabbits per time point at single doses of 600 mu g/eye to evaluate ocular PK, which was evaluated using autoradiography until 48 h post-dose. Plasma concentrations after ocular administration in six rabbits, three rats, and three beagle dogs with single doses of 400 mu g, 25 mu g, and 100 mu g, respectively, were investigated for 24 h. The retinal concentration of [14C] enavogliflozin reached Cmax at 2.0 h with an elimination half-life of 32.5 h, which remained above the IC50 value of sodium-dependent glucose transporter 2 until 24 h post-dose. In the plasma of rabbits, the fastest Tmax of 0.5 h and a 3.6 h half-life were observed among animal species. The relative bioavailability in rabbits after ocular administration was 3.4 compared to oral administration. Ocular administration of enavogliflozin could be a potential therapeutic route for diabetic retinal complications, based on relative bioavailability and effective delivery to the posterior ocular segment. DWRX2008 would be applicable to humans with favorable PK profiles and minimal systemic adverse effect.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.